Us Bancorp \De\ Supernus Pharmaceuticals, Inc. Transaction History

Us Bancorp \De\

$78.3 Billion
Q2 2025

A detailed history of Us Bancorp \De\ transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 5,565 shares of SUPN stock, worth $229,500. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,565

Previous 6,161 9.67%

Holding current value

$229,500

Previous $201,000 12.94%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 23, 2025	SELL	$30.29 - $33.43 $18,052 - $19,924	-596 Reduced 9.67%	5,565 $175,000
Q1 2025 May 08, 2025	BUY	$31.17 - $40.0 $3,241 - $4,160	104 Added 1.72%	6,161 $201,000
Q4 2024 Feb 05, 2025	BUY	$31.89 - $37.83 $574 - $680	18 Added 0.3%	6,057 $219,000
Q3 2024 Oct 28, 2024	BUY	$25.77 - $35.16 $1,958 - $2,672	76 Added 1.27%	6,039 $188,000
Q2 2024 Aug 06, 2024	SELL	$25.99 - $33.85 $2,287 - $2,978	-88 Reduced 1.45%	5,963 $159,000
Q1 2024 May 07, 2024	BUY	$27.11 - $35.17 $12,280 - $15,932	453 Added 8.09%	6,051 $206,000
Q4 2023 Feb 09, 2024	SELL	$22.72 - $29.68 $1,544 - $2,018	-68 Reduced 1.2%	5,598 $162,000
Q3 2023 Nov 03, 2023	SELL	$27.57 - $32.91 $10,614 - $12,670	-385 Reduced 6.36%	5,666 $156,000
Q2 2023 Aug 09, 2023	SELL	$29.91 - $38.73 $6,520 - $8,443	-218 Reduced 3.48%	6,051 $181,000
Q1 2023 May 09, 2023	BUY	$34.93 - $42.03 $32,240 - $38,793	923 Added 17.27%	6,269 $227,000
Q4 2022 Feb 13, 2023	SELL	$31.09 - $37.88 $15,949 - $19,432	-513 Reduced 8.76%	5,346 $190,000
Q3 2022 Oct 27, 2022	SELL	$28.79 - $35.41 $24,039 - $29,567	-835 Reduced 12.47%	5,859 $198,000
Q2 2022 Aug 01, 2022	SELL	$25.33 - $34.25 $72,925 - $98,605	-2,879 Reduced 30.07%	6,694 $194,000
Q1 2022 May 11, 2022	SELL	$28.51 - $32.9 $87,725 - $101,233	-3,077 Reduced 24.32%	9,573 $309,000
Q4 2021 Feb 11, 2022	SELL	$26.37 - $34.22 $7,014 - $9,102	-266 Reduced 2.06%	12,650 $369,000
Q3 2021 Nov 10, 2021	SELL	$23.54 - $31.39 $18,102 - $24,138	-769 Reduced 5.62%	12,916 $344,000
Q2 2021 Aug 05, 2021	BUY	$26.72 - $33.19 $16,539 - $20,544	619 Added 4.74%	13,685 $421,000
Q1 2021 Apr 28, 2021	BUY	$24.15 - $31.45 $43,083 - $56,106	1,784 Added 15.81%	13,066 $342,000
Q4 2020 Feb 04, 2021	SELL	$17.7 - $25.81 $29,452 - $42,947	-1,664 Reduced 12.85%	11,282 $284,000
Q3 2020 Nov 10, 2020	SELL	$20.2 - $25.05 $77,204 - $95,741	-3,822 Reduced 22.79%	12,946 $269,000
Q2 2020 Aug 07, 2020	SELL	$17.09 - $24.89 $59,832 - $87,139	-3,501 Reduced 17.27%	16,768 $399,000
Q1 2020 May 13, 2020	SELL	$14.45 - $24.69 $7,615 - $13,011	-527 Reduced 2.53%	20,269 $365,000
Q4 2019 Feb 04, 2020	SELL	$19.93 - $29.13 $115,633 - $169,012	-5,802 Reduced 21.81%	20,796 $493,000
Q3 2019 Nov 08, 2019	SELL	$25.47 - $33.37 $143,599 - $188,140	-5,638 Reduced 17.49%	26,598 $732,000
Q2 2019 Aug 13, 2019	SELL	$29.96 - $38.87 $240,219 - $311,659	-8,018 Reduced 19.92%	32,236 $1.07 Million
Q1 2019 May 08, 2019	BUY	$32.77 - $41.99 $139,862 - $179,213	4,268 Added 11.86%	40,254 $1.41 Million
Q4 2018 Feb 13, 2019	BUY	$30.84 - $49.51 $224,114 - $359,789	7,267 Added 25.3%	35,986 $1.2 Million
Q3 2018 Nov 01, 2018	BUY	$42.7 - $56.55 $206,924 - $274,041	4,846 Added 20.3%	28,719 $1.45 Million
Q2 2018 Aug 08, 2018	SELL	$44.1 - $59.85 $40,439 - $54,882	-917 Reduced 3.7%	23,873 $1.43 Million
Q1 2018 May 08, 2018	SELL	$37.15 - $46.9 $107,809 - $136,103	-2,902 Reduced 10.48%	24,790 $1.14 Million
Q4 2017 Feb 02, 2018	SELL	$36.4 - $42.6 $159,832 - $187,056	-4,391 Reduced 13.69%	27,692 $1.1 Million
Q3 2017 Nov 13, 2017	BUY	$36.75 - $49.65 $1.18 Million - $1.59 Million	32,083	32,083 $1.28 Million

Others Institutions Holding SUPN

# of Institutions

308

Shares Held

60.1M

Call Options Held

8.8K

Put Options Held

6.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.21B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account